<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):&nbsp;<B>
June 7, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B><U>Skinny
Nutritional Corp.<BR>
</U></B></FONT>(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMMISSION FILE NUMBER<B>:&nbsp;&nbsp;<U>0-51313</U></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Nevada</TD>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">88-0314792</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center">Three Bala Plaza East, Suite 101</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Bala Cynwyd, PA 19004</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">(Address and zip code of principal executive offices)</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>(610)
784-2000<BR>
</U></B>(Registrant&rsquo;s telephone number, including area code </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED
        TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><B></B> Written communications
        pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><B></B> Soliciting material pursuant
        to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><B></B> Pre-commencement communications
        pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><B></B> Pre-commencement communications
        pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 10%; vertical-align: top; font-size: 10pt; font-weight: bold">Item 1.01</TD>
    <TD STYLE="width: 90%; padding-left: 8.8pt; font-size: 10pt; font-weight: bold">Entry into a Material Definitive Agreement.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-left: 8.8pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">On June 7, 2012, Skinny Nutritional Corp.
        (the         &ldquo;Company&rdquo;) and Ironridge Global IV, Ltd. (&ldquo;Ironridge&rdquo; or &ldquo;Creditor&rdquo;)<FONT STYLE="color: black">
        entered into a settlement agreement regarding a previously entered </FONT>Order for Approval of Stipulation for Settlement
        of         Claims         (the &ldquo;Stipulation&rdquo;) between the Company and Ironridge that was entered into on January
        23, 2012         and approved by the         Superior Court of the State of California, County of Los Angeles, Central
        District. The agreement         seeks to resolve the Company&rsquo;s         future obligations under such Stipulation. The
        agreement provides for the         following transactions in furtherance of its purpose:         (i) the sale by Creditor to
        third parties of 50,000,000 shares         of the Common Stock of the Company at a price of $.007 per share         for
        aggregate gross proceeds of $350,000; (ii) the         issuance by the Company to Ironridge of 20,000,000 additional shares
        of Common         Stock of the Company pursuant to the         Stipulation; and (iii) the payment by the Company to Creditor
        of $350,000. The agreement provides         that, upon payment         in full by the Company to Creditor of all amounts,
        and         any required performance by third parties, the Stipulation will be fully performed and the Company will
        have         no         further         obligations         thereunder to         Creditor. The agreement also includes a
        mutual general release of         claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">Ironridge has notified the Company that required third party actions under the agreement were not fully
completed.&nbsp; The Company believes that it has performed its obligations under the agreement and that any failure to perform
by third parties is not within its control. Ironridge has issued correspondence to the Company claiming additional shares for the
alleged breach. The Company disputes such claims.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">The foregoing summary of the agreement and the
        transactions contemplated thereby does not purport to be complete and is subject to, and is qualified in its entirety by, the agreement,
        which is filed as Exhibit 10.1 to this Current Report on Form 8-K.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 10%; vertical-align: top; font-weight: bold">Item 2.03</TD>
    <TD STYLE="width: 90%; padding-right: 4.85pt; padding-left: 8.8pt; font-weight: bold">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 4.85pt; padding-left: 8.8pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">In connection with the transactions described
        in Item 1.01 of this Current Report, on June 7, 2012, the Company obtained an increased commitment in the principal amount of $300,000
        from its lender, United Capital Funding Corp., and a loan in the principal amount of $50,000 from Michael Salaman, the Company&rsquo;s
        Chief Executive Officer and Chairman. These loans are evidenced by promissory notes issued by the Company. Both of the above promissory
        notes are due and payable in 60 days and bear interest at the rate of 12% per annum. The promissory note issued to United Capital
        Funding Corp. is secured by all of the Company&rsquo;s inventory and accounts receivable. United Capital Funding Corp. currently
        provides the Company with a credit line under a Factoring Agreement, which credit is secured by all of the Company&rsquo;s inventory
        and accounts receivable under a Loan Agreement dated as of April 1, 2009. The repayment of the promissory note issued to United
        Capital Funding Corp. is personally guaranteed by Mr. Salaman.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">The foregoing summary of the promissory notes
        do not purport to be complete and is subject to, and is qualified in its entirety by, the actual forms of promissory notes, which
        are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 10%; vertical-align: top; font-weight: bold">Item&nbsp;3.02</TD>
    <TD STYLE="width: 90%; padding-right: 4.85pt; padding-left: 8.8pt; font-weight: bold">Unregistered Sales of Equity Securities.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 4.85pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">On January 27, 2012, the Company filed a Current
        Report on Form 8-K reporting that it had issued an aggregate of 65,100,000 shares of the Company&rsquo;s common stock, par value
        $0.001 per share (the &ldquo;Initial Shares&rdquo;), to Ironridge, in settlement of $1,255,231.64 in <I>bona fide</I> accounts
        payable of the Company (the &ldquo;Accounts Payable&rdquo;). As previously reported, the Initial Shares were issued pursuant to
        the Stipulation. In addition, as previously reported, the Stipulation provides that for every ten million shares of the Company&rsquo;s
        Common Stock that trade during the a defined calculation period, or if at any time during such period a daily VWAP is below 80%
        of the closing price on the day before the issuance date, the Company will immediately issue additional shares (each, an &ldquo;Additional
        Issuance&rdquo;), subject to a 9.99% beneficial ownership limitation specified in the Stipulation. Accordingly, pursuant to the
        adjustment mechanism specified in the Stipulation, on June 4, 2012, the Company issued an additional 21,000,000 shares of Common
        Stock to Ironridge. Further, in connection with the agreement described above under Item 1.01 of this Current Report, the Company
        issued an additional 20,000,000 shares of Common Stock to Ironridge on June 8, 2012 pursuant to the adjustment mechanism. The Additional
        Issuances were exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 3(a)(10)
        thereof, as an issuance of securities in exchange for bona fide outstanding claims, where the terms and conditions of such issuance
        are approved by a court after a hearing upon the fairness of such terms and conditions.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 4.3pt">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.85pt 0pt 8.8pt">Pursuant to the promissory note issued to
        United         Capital Funding Corp. as described in Item 2.03 of this Current Report, the Company agreed to issue
        3,000,000         shares of Common Stock to         United Capital Funding Corp. Such issuance is exempt from the
        registration         requirements of the         Securities Act of 1933, as amended, pursuant         to Section 4(2)
        thereof, inasmuch as the         Company believed the acquirer         is an accredited investor and the securities will be
        issued         without any form         of         general solicitation or general         advertising.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 11%; font-weight: bold">Item 9.01</TD>
    <TD STYLE="width: 89%; padding-left: 4.55pt; font-weight: bold">Financial Statements and Exhibits.&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 11%; text-align: center">(d)</TD>
    <TD STYLE="width: 89%; padding-left: 4.3pt">The following exhibits are filed herewith</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 11%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 12%; vertical-align: top; border-bottom: windowtext 1pt solid; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 77%; border-bottom: windowtext 1pt solid; padding-left: 3pt; font-weight: bold">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-left: 3pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">4.1</TD>
    <TD STYLE="padding-left: 3pt">Promissory Note Issued to United Capital Funding Corp.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">4.2</TD>
    <TD STYLE="padding-left: 3pt">Promissory Note Issued to Michael Salaman</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">10.1</TD>
    <TD STYLE="padding-left: 3pt">Settlement Agreement</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; font-weight: bold">Skinny Nutritional Corp.</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>By:&nbsp; /s/ Michael Salaman</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Michael Salaman</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR>
    <TD>&nbsp;Date: &nbsp; June 13, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 12%; vertical-align: top; border-bottom: windowtext 1pt solid; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 87%; border-bottom: windowtext 1pt solid; padding-left: 3pt; font-weight: bold">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-left: 3pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">4.1</TD>
    <TD STYLE="padding-left: 3pt">Promissory Note Issued to United Capital Funding Corp.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">4.2</TD>
    <TD STYLE="padding-left: 3pt">Promissory Note Issued to Michael Salaman</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">10.1</TD>
    <TD STYLE="padding-left: 3pt">Settlement Agreement</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v315905_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 24063}]
{"company-data": {"conformed-name": "Skinny Nutritional Corp.", "cik": "0001176325", "assigned-sic": "5141", "irs-number": "233100268", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51313", "film-number": "12905813"}, "business-address": {"street1": "3 BALA PLAZA EAST", "street2": "SUITE 117", "city": "BALA CYNWYD", "state": "PA", "zip": "19004", "phone": "610-784-2000"}, "mail-address": {"street1": "3 BALA PLAZA EAST", "street2": "SUITE 117", "city": "BALA CYNWYD", "state": "PA", "zip": "19004"}, "former-company": {"former-conformed-name": "CREATIVE ENTERPRISES INTERNATIONAL INC", "date-changed": "20020625"}}
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
June 7, 2012
Skinny
Nutritional Corp.
(Exact name of registrant as specified in its charter)
COMMISSION FILE NUMBER
:
0-51313
Nevada
88-0314792
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
Three Bala Plaza East, Suite 101
Bala Cynwyd, PA 19004
(Address and zip code of principal executive offices)
(610)
784-2000
(Registrant's telephone number, including area code
CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED
        TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:
¨
Written communications
        pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant
        to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications
        pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications
        pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement.
On June 7, 2012, Skinny Nutritional Corp.
        (the         "Company") and Ironridge Global IV, Ltd. ("Ironridge" or "Creditor")
entered into a settlement agreement regarding a previously entered
Order for Approval of Stipulation for Settlement
        of         Claims         (the "Stipulation") between the Company and Ironridge that was entered into on January
        23, 2012         and approved by the         Superior Court of the State of California, County of Los Angeles, Central
        District. The agreement         seeks to resolve the Company's         future obligations under such Stipulation. The
        agreement provides for the         following transactions in furtherance of its purpose:         (i) the sale by Creditor to
        third parties of 50,000,000 shares         of the Common Stock of the Company at a price of $.007 per share         for
        aggregate gross proceeds of $350,000; (ii) the         issuance by the Company to Ironridge of 20,000,000 additional shares
        of Common         Stock of the Company pursuant to the         Stipulation; and (iii) the payment by the Company to Creditor
        of $350,000. The agreement provides         that, upon payment         in full by the Company to Creditor of all amounts,
        and         any required performance by third parties, the Stipulation will be fully performed and the Company will
        have         no         further         obligations         thereunder to         Creditor. The agreement also includes a
        mutual general release of         claims.
Ironridge has notified the Company that required third party actions under the agreement were not fully
completed.  The Company believes that it has performed its obligations under the agreement and that any failure to perform
by third parties is not within its control. Ironridge has issued correspondence to the Company claiming additional shares for the
alleged breach. The Company disputes such claims.
The foregoing summary of the agreement and the
        transactions contemplated thereby does not purport to be complete and is subject to, and is qualified in its entirety by, the agreement,
        which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
In connection with the transactions described
        in Item 1.01 of this Current Report, on June 7, 2012, the Company obtained an increased commitment in the principal amount of $300,000
        from its lender, United Capital Funding Corp., and a loan in the principal amount of $50,000 from Michael Salaman, the Company's
        Chief Executive Officer and Chairman. These loans are evidenced by promissory notes issued by the Company. Both of the above promissory
        notes are due and payable in 60 days and bear interest at the rate of 12% per annum. The promissory note issued to United Capital
        Funding Corp. is secured by all of the Company's inventory and accounts receivable. United Capital Funding Corp. currently
        provides the Company with a credit line under a Factoring Agreement, which credit is secured by all of the Company's inventory
        and accounts receivable under a Loan Agreement dated as of April 1, 2009. The repayment of the promissory note issued to United
        Capital Funding Corp. is personally guaranteed by Mr. Salaman.
The foregoing summary of the promissory notes
        do not purport to be complete and is subject to, and is qualified in its entirety by, the actual forms of promissory notes, which
        are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K.
Item 3.02
Unregistered Sales of Equity Securities.
On January 27, 2012, the Company filed a Current
        Report on Form 8-K reporting that it had issued an aggregate of 65,100,000 shares of the Company's common stock, par value
        $0.001 per share (the "Initial Shares"), to Ironridge, in settlement of $1,255,231.64 in
bona fide
accounts
        payable of the Company (the "Accounts Payable"). As previously reported, the Initial Shares were issued pursuant to
        the Stipulation. In addition, as previously reported, the Stipulation provides that for every ten million shares of the Company's
        Common Stock that trade during the a defined calculation period, or if at any time during such period a daily VWAP is below 80%
        of the closing price on the day before the issuance date, the Company will immediately issue additional shares (each, an "Additional
        Issuance"), subject to a 9.99% beneficial ownership limitation specified in the Stipulation. Accordingly, pursuant to the
        adjustment mechanism specified in the Stipulation, on June 4, 2012, the Company issued an additional 21,000,000 shares of Common
        Stock to Ironridge. Further, in connection with the agreement described above under Item 1.01 of this Current Report, the Company
        issued an additional 20,000,000 shares of Common Stock to Ironridge on June 8, 2012 pursuant to the adjustment mechanism. The Additional
        Issuances were exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 3(a)(10)
        thereof, as an issuance of securities in exchange for bona fide outstanding claims, where the terms and conditions of such issuance
        are approved by a court after a hearing upon the fairness of such terms and conditions.
Pursuant to the promissory note issued to
        United         Capital Funding Corp. as described in Item 2.03 of this Current Report, the Company agreed to issue
        3,000,000         shares of Common Stock to         United Capital Funding Corp. Such issuance is exempt from the
        registration         requirements of the         Securities Act of 1933, as amended, pursuant         to Section 4(2)
        thereof, inasmuch as the         Company believed the acquirer         is an accredited investor and the securities will be
        issued         without any form         of         general solicitation or general         advertising.
2
Item 9.01
Financial Statements and Exhibits.
(d)
The following exhibits are filed herewith
Exhibit No.
Description
4.1
Promissory Note Issued to United Capital Funding Corp.
4.2
Promissory Note Issued to Michael Salaman
10.1
Settlement Agreement
3
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
Skinny Nutritional Corp.
By:  /s/ Michael Salaman
Name: Michael Salaman
Title:   Chief Executive Officer
Date:   June 13, 2012
4
EXHIBIT INDEX
Exhibit No.
Description
4.1
Promissory Note Issued to United Capital Funding Corp.
4.2
Promissory Note Issued to Michael Salaman
10.1
Settlement Agreement
5